Article thumbnail

Methodological considerations in quantification of oncological FDG PET studies

By Dennis Vriens, Eric P. Visser, Lioe-Fee de Geus-Oei and Wim J. G. Oyen
Topics: Review Article
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:2886126
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. 18F-FDG PET in non-Hodgkin’s lymphoma: qualitative or quantitative?
  2. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma.
  3. (2010). A comparison of normalization effects on three whole-body cylindrical 3D PET systems. Phys Med Biol 2000;45:3253–66. Eur J Nucl Med Mol Imaging
  4. (2010). A modeling method to improve quantitation of fluorodeoxyglucose uptake in heterogeneous tumor tissue.
  5. (1974). A new look at the statistical model identification.
  6. A novel approach for reduction of brown fat uptake on FDG PET.
  7. A novel iterative method for lesion delineation and volumetric quantification with FDG PET.
  8. (2009). A randomised controlled trial assessing the effect of oral diazepam on 18F-FDG uptake in the neck and upper chest region. Mol Imaging Biol
  9. (2004). Advances in scatter correction for 3D PET/CT.
  10. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?
  11. (1999). Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction.
  12. (2009). Benefit of time-of-flight imaging with the new
  13. (2008). Blood flow and glucose metabolism in stage IV breast cancer: heterogeneity of response during chemotherapy. Mol Imaging Biol
  14. (1997). Breast imaging with fluorine-18-FDG PET: quantitative image analysis.
  15. (2008). Cascades of pile-up and dead time. Appl Radiat Isot
  16. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
  17. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer.
  18. (2002). Clinical review: complications and risk factors of peripheral arterial catheters used for haemodynamic monitoring in anaesthesia and intensive care medicine. Crit Care
  19. Cluster analysis in kinetic modelling of the brain: a noninvasive alternative to arterial sampling.
  20. Cold-activated brown adipose tissue in healthy men.
  21. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas.
  22. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET.
  23. Comparison of image-derived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies.
  24. Comparison of imaging protocols for 18F-FDG PET/CT in overweight patients: optimizing scan duration versus administered dose.
  25. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
  26. Constant ambient temperature of 24 degrees C significantly reduces FDG uptake by brown adipose tissue in children scanned during the winter.
  27. Correction methods for random coincidences in fully 3D whole-body PET: impact on data and image quality.
  28. CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET.
  29. (1996). Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction.
  30. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.
  31. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.
  32. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.
  33. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial.
  34. (1995). Effects of scatter on model parameter estimates in 3D PET studies of the human brain.
  35. (1996). Enhanced FDG-PET tumor imaging with correlation-coefficient filtered influx-constant images.
  36. (1992). Errors introduced by tissue heterogeneity in estimation of local cerebral glucose utilization with current kinetic models of the [18F]fluorodeoxyglucose method.
  37. (1978). Estimating dimension of a model.
  38. (1992). Evaluation of liver tumors using fluorine18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment.
  39. (1997). Evaluation of two population-based input functions for quantitative neurological FDG PET studies.
  40. Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling.
  41. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies.
  42. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection.
  43. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors.
  44. Functional brown adipose tissue in healthy adults.
  45. (2002). Fundamentals of quantitative PET data analysis. Curr Pharm Des
  46. Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for [18F] fluorodeoxyglucose and [11C]deoxyglucose.
  47. (1983). Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.
  48. High and typical 18F-FDG bowel uptake in patients treated with metformin.
  49. How should we analyse FDG PET studies for monitoring tumour response?
  50. Identification and importance of brown adipose tissue in adult humans.
  51. Image-derived input functions for determination of MRGlu in cardiac (18)F-FDG PET scans.
  52. Impact of angiogenesis-related gene expression on the tracer kinetics of 18F-FDG in colorectal tumors.
  53. Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET.
  54. Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values.
  55. Influence of the blood glucose concentration on FDG uptake in cancer—a PET study.
  56. Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically.
  57. Local motion correction for lung tumours in PET/CT—first results.
  58. (2007). Low-dose oral propranolol could reduce brown adipose tissue F-18 FDG uptake in patients undergoing PET scans. Clin Nucl Med
  59. (1995). Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology
  60. Measurement of 18F-FDG concentrations in blood samples: comparison of direct calibration and standard solution methods.
  61. (1999). Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and
  62. (2002). Measurement of glucose consumption using [(18) F]fluorodeoxyglucose. Methods
  63. Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods.
  64. (1990). Measuring PET scanner sensitivity: relating count rates to image signal-to-noise ratios using noise equivalent counts.
  65. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET.
  66. (1993). Models for computer simulation studies of input functions for tracer kinetic modeling with positron emission tomography.
  67. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods.
  68. NEC: some coincidences are more equivalent than others.
  69. (1998). Non-invasive estimation of the net influx constant using the standardized uptake value for quantification of FDG uptake of tumours.
  70. Noninvasive estimation of FDG input function for quantification of cerebral metabolic rate of glucose: optimization and multicenter evaluation.
  71. (1991). Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs.
  72. (1999). On the use of image-derived input functions in oncological fluorine-18 fluorodeoxyglucose positron emission tomography studies.
  73. (2010). Optimization of whole-body positron emission tomography imaging by using delayed 2-deoxy-2-[F-18]fluoro-D: -glucose injection following I.V. insulin in diabetic patients. Mol Imaging Biol 2006;8:348–54. 1422
  74. Optimizing injected dose in clinical PET by accurately modeling the counting-rate response functions specific to individual patient scans.
  75. Partial-volume effect in PET tumor imaging.
  76. Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET.
  77. (2010). Performance characteristics of a new LSO PET/CT scanner with extended axial field-of-view and PSF reconstruction.
  78. (2007). Performance Measurements of Positron Emission Tomographs (PET).
  79. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities.
  80. (2007). PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol
  81. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients.
  82. Physiological uptake of [18F]fluorodeoxyglucose in the neck and upper chest region: are there predictive characteristics?
  83. (2003). Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol
  84. (2008). Predictive and prognostic value of FDG-PET. Cancer Imaging
  85. (2005). Premedication to block [(18)F]FDG uptake in the brown adipose tissue of pediatric and adolescent patients. Pediatr Radiol
  86. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0.
  87. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET.
  88. Quantification method in [18F]fluorodeoxyglucose brain positron emission tomography using independent component analysis.
  89. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters.
  90. (1996). Quantification of serial tumor glucose metabolism.
  91. (2008). Quantitative effects of contrast enhanced CT attenuation correction on PET SUV measurements. Mol Imaging Biol
  92. (1998). Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Annals of the ICRP.
  93. Recommendations on the use of 18F-FDG PET in oncology.
  94. Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propranolol.
  95. (2002). Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose. Mol Imaging Biol
  96. Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors.
  97. (2008). Respiratory motion in positron emission tomography/computed tomography: a review. Semin Nucl Med
  98. (1997). Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding.
  99. Short dynamic FDG-PET imaging protocol for patients with lung cancer.
  100. Shortened PET data acquisition protocol for the quantification of 18FFDG kinetics.
  101. Simplified kinetic analysis of tumor 18F-FDG uptake: a dynamic approach.
  102. (1996). Simplified measurement of deoxyglucose utilization rate.
  103. (1994). Standardized uptake values of FDG: body surface area correction is preferable to body weight correction.
  104. (1996). Standardized uptake values of fluorine-18 fluorodeoxyglucose: the value of different normalization procedures.
  105. (1993). Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology
  106. (1995). SUV: standard uptake or silly useless value?
  107. (1977). The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.
  108. (1994). The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?
  109. The FDG lumped constant in normal human brain.
  110. (1993). The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas.
  111. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multicentre trials.
  112. (1979). Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-Dglucose: validation of method.
  113. (2005). Tracer kinetic modeling in nuclear medicine: theory and applications.
  114. (1999). Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging
  115. Urinary fluorine-18 fluorodeoxyglucose excretion with and without intravenous application of furosemide.
  116. Use of arterialised venous instead of arterial blood for measurement of myocardial glucose metabolism during euglycaemic-hyperinsulinaemic clamping.
  117. What is in a number? The FDG lumped constant in the rat brain.
  118. (2003). X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med